Pre-Meeting Categorical Seminars

Additional registration fees may apply. Categorical seminar is included for Weekend Only Attendees. *Members who are also members of a Council or Center will receive a $20 discount when registering online for a Physician/Scientist Categorical.
SNMMI's Annual Meeting offers full-day categorical seminars to provide you with a deeper level of understanding as you examine a single topic of clinical, scientific, or academic interest.

AI in the Era of Personalized Nuclear Medicine
Sponsored by Physics, Instrumentation and Data Sciences Council, CMIIT and Pediatric Imaging Council
The confluence of Artificial Intelligence and Big Data has emerged as one of the most exciting and impactful technological developments of the last couple of years. Yet, the adoption of this technology in nuclear medicine and molecular imaging has been significantly slower than in other areas of medical imaging (e.g., CT, MR) and healthcare in general.
In this Categorical, we propose to cover the basics of Deep Learning, provide the audience with basic guidance on how to implement AI technologies in one's practice, Assess Medical Data Security and ethical challenges, Learn how AI can yield significant dose reduction in pediatric imaging and higher sensitivity in Personalized Medicine.  Finally, we also cover the promise and limitations of AI in lesion detection, segmentation, characterization.

A New Decade of Molecular Hybrid Imaging in Orthopedics and Rheumatology: Focus on bone and infection/inflammation
Sponsored by General Clinical Nuclear Medicine Council and British Institute of Radiology
This categorical session consists of 4 thematically linked mini sessions, updating the audience on technical advances as well as key clinical applications of PET/CT and SPECT/CT in orthopedics, infectious disease, and rheumatology. In the first part, the recent progress in radiopharmaceutical development for musculoskeletal imaging applications and advances in engineering and physics in SPECT/CT will be presented. Next, the clinical use of bone SPECT/CT in orthopedics is illustrated with a focus on the role of biomechanics in upper and lower limb joint related conditions. A separate talk will summarize applications of bone PET/CT in orthopedics and related specialties. After lunch, the topic of bone and prosthesis related infections will be addressed, emphasizing the clinical indications, imaging algorithms, and impact in patient management. The last part of this categorical session reviews the role of FDG-PET/CT in polymyalgia rheumatica and rheumatoid arthritis, and NaF-PET/CT in rare bone disease (fibrous dysplasia, Paget’s disease, bone viability).

Clinical Issues Effecting Diagnosis and Management of Differentiated Thyroid Cancer
Sponsored by Therapy Center of Excellence AND Committee on Radioiodine Theranostics
I-131 therapy remains the most frequently perform radioisotope therapy in the specialty of Nuclear Medicine.  Many new articles have been published that are controversial and affect our practice of I-131 therapies for differentiated thyroid cancer and benign disease. The objective of this Categorical Session will be a timely discussion of the many of these new publications, and this will include a discussion of the clinical impact and controversies of those changes.  The intended audience is nuclear medicine physicians and technologists involved in the management of patients with differentiated thyroid cancer.  This session addresses the needs of these individuals to understand the Martinique Principles from the ATA, ETA, EANM, and SNMMI and other publications and guidelines and how they may affect their practices performance and patient outcomes.   

Labeling Strategies for Radiopharmaceutical Synthesis: State-of-the-art and Future Prospects
Sponsored by Radiopharmaceutical Sciences Council
It is an exciting and transformative time in the fields of Nuclear Medicine and the Radiopharmaceutical Sciences! New radiopharmaceuticals continue to be approved by the U.S. Food and Drug Administration (FDA), including new theranostics for cancer treatment, that are transforming the lives of the patients we diagnose and treat in our clinics every day. This is transforming Nuclear Medicine from a research technique to a powerful standard of care. This growth is changing radionuclide supply chains and which radiopharmaceuticals are being routinely synthesized in the global manufacturing network. At the same time, a rapidly changing regulatory environment is also changing how radiopharmaceuticals are manufactured and dispensed. It is therefore imperative that radiopharmaceutical scientists and nuclear medicine professionals keep up to date with state-of-the-art practices in labeling strategies and radiopharmaceutical synthesis to meet the rapidly growing demands for nuclear medicine imaging agents and radiotherapeutics. To adequately inform attendees about the breadth of radionuclides and radiopharmaceuticals in use today, this all-day categorical session will have 7 experts give talks covering everything from fundamental design of radiopharmaceuticals to strategies for labeling of specific bioactive molecules, and synthesis of PET radiopharmaceuticals, SPECT radiopharmaceuticals and radiotherapeutics. It will conclude with a panel discussion and an opportunity for questions and answers from attendees.

Neurodegeneration: From Current Clinical Applications to New Advancements
Sponsored by Brain Imaging Council
This program content was idealized to provide a full review and comprehension of the role of molecular imaging in Neurodegenerative diseases. We believe this will be a tremendous opportunity for learning and improving skills and competency. The content is focused on general participants interested in improving their knowledge in neurodegeneration, as well as in specialists, with the more recent updates in the field.

Nuclear Cardiology in 2020 and Beyond: Image Guided Decision Making
Sponsored by Cardiovascular Council, Correlative Imaging Council, and Physics, Instrumentation and Data Sciences Council
This full-day categorical course has five themes centered on the topics of: [1] coronary artery disease evaluation (role of clinical risk assessment and biomarkers, SPECT-CT, PET, CCTA and case review), [2] cardiac sarcoidosis (patient preparation, multimodality approach and case review), [3] cardiac infections (valvular endocarditis, other cardiac device infections, correlative imaging on CT and case review), [4] cardiac amyloidosis (imaging protocols, clinical presentation/pathophysiology/treatment, and case review), and [5] microvascular chest pain and quantitative blood flow estimation (protocols/image analysis, treatment/physiology, and case review). Multimodality imaging will be emphasized and include SPECT, PET, CT and CMR imaging.

Pearls and Pitfalls of Common Nuclear Medicine Procedures
Sponsored by Advanced Associate Council and General Clinical Nuclear Medicine Council
The objective of this course is to understand the best practice and challenges in performing common nuclear medicine procedures and improve the quality of nuclear medicine performed at local institutions. 15 speakers, 30 minutes per speaker, 5 topics, each covered by technologist, Nuclear Medicine Advanced Associates (NMAAs) and physician. The focus will be on quality of nuclear medicine procedures fostered by different level providers working together.

Targeted Molecular Imaging and Radiotheranostics of Prostate Cancer
Sponsored by Therapy Center of Excellence, PET Center of Excellence and Correlative Imaging Council
There has been tremendous growth of molecular imaging and therapy of prostate cancer.  Many different PET radiopharmaceuticals are now widely available and provide accurate identification of biochemical recurrent prostate cancer.  Several PSMA and other targeted PET agents are also being used clinically and in research settings.  In addition to molecular imaging radiopharmaceuticals, many radiotherapeutic options are available for both osseous and soft tissue prostate cancer metastatic disease.  This rapid growth in both imaging and therapy can be difficult for both patients and providers to navigate and understand which option is best.  This course will cover the currently available agents as well as how molecular imaging and therapy will be affected in the short term.  An oncologist perspective will be included in the session and there will be group discussions with the speakers to help the audience understand the various routes available for optimal patient care.